186 related articles for article (PubMed ID: 7530170)
1. Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19.
Vlasveld LT; Hekman A; Vyth-Dreese FA; Melief CJ; Sein JJ; Voordouw AC; Dellemijn TA; Rankin EM
Cancer Immunol Immunother; 1995 Jan; 40(1):37-47. PubMed ID: 7530170
[TBL] [Abstract][Full Text] [Related]
2. Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model.
Vuist WM; v Buitenen F; de Rie MA; Hekman A; Rümke P; Melief CJ
Cancer Res; 1989 Jul; 49(14):3783-8. PubMed ID: 2472198
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of CD3 x CD19 bispecific monoclonal antibody (BsAb) in a clonogenic assay: the effect of repeated addition of BsAb and interleukin-2.
Haagen IA; Geerars AJ; de Lau WB; Bast BJ; de Gast BC
Blood; 1995 Jun; 85(11):3208-12. PubMed ID: 7538821
[TBL] [Abstract][Full Text] [Related]
4. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation.
Soiffer RJ; Murray C; Cochran K; Cameron C; Wang E; Schow PW; Daley JF; Ritz J
Blood; 1992 Jan; 79(2):517-26. PubMed ID: 1730094
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.
Hooijberg E; van den Berk PC; Sein JJ; Wijdenes J; Hart AA; de Boer RW; Melief CJ; Hekman A
Cancer Res; 1995 Feb; 55(4):840-6. PubMed ID: 7531616
[TBL] [Abstract][Full Text] [Related]
6. Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2.
Hooijberg E; Sein JJ; van den Berk PC; Hart AA; van der Valk MA; Kast WM; Melief CJ; Hekman A
Cancer Res; 1995 Jun; 55(12):2627-34. PubMed ID: 7540106
[TBL] [Abstract][Full Text] [Related]
7. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies.
Bohlen H; Hopff T; Manzke O; Engert A; Kube D; Wickramanayake PD; Diehl V; Tesch H
Blood; 1993 Sep; 82(6):1803-12. PubMed ID: 7691238
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo antitumor activity of a chimeric anti-CD19 antibody.
Pietersz GA; Wenjun L; Sutton VR; Burgess J; McKenzie IF; Zola H; Trapani JA
Cancer Immunol Immunother; 1995 Jul; 41(1):53-60. PubMed ID: 7543822
[TBL] [Abstract][Full Text] [Related]
9. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
[TBL] [Abstract][Full Text] [Related]
10. Lymphocyte activation and serine-esterase induction following recombinant interleukin-2 infusion for lymphomas and acute leukaemias.
Lim SH; Worman C; Jewell A; Tsakona C; Giles FJ; Goldstone A
Cancer Immunol Immunother; 1991; 33(2):133-7. PubMed ID: 2036661
[TBL] [Abstract][Full Text] [Related]
11. Preclinical investigation of the antitumour effects of anti-CD19-idarubicin immunoconjugates.
Rowland AJ; Pietersz GA; McKenzie IF
Cancer Immunol Immunother; 1993 Aug; 37(3):195-202. PubMed ID: 7687521
[TBL] [Abstract][Full Text] [Related]
12. CD8 T cell activation after intravenous administration of CD3 x CD19 bispecific antibody in patients with non-Hodgkin lymphoma.
de Gast GC; Haagen IA; van Houten AA; Klein SC; Duits AJ; de Weger RA; Vroom TM; Clark MR; Phillips J; van Dijk AJ
Cancer Immunol Immunother; 1995 Jun; 40(6):390-6. PubMed ID: 7543021
[TBL] [Abstract][Full Text] [Related]
13. Two distinct mechanisms of antitumor activity mediated by the combination of interleukin 2 and monoclonal antibodies.
Vuist WM; van Buitenen F; Hekman A; Melief CJ
Cancer Res; 1990 Sep; 50(18):5767-72. PubMed ID: 1697500
[TBL] [Abstract][Full Text] [Related]
14. Killing of autologous B-lineage malignancy using CD3 x CD19 bispecific monoclonal antibody in end stage leukemia and lymphoma.
Haagen IA; Geerars AJ; de Lau WB; Clark MR; van de Griend RJ; Bast BJ; de Gast BC
Blood; 1994 Jul; 84(2):556-63. PubMed ID: 7517719
[TBL] [Abstract][Full Text] [Related]
15. Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (alpha CD3/alpha CD19).
Haagen IA; van de Griend R; Clark M; Geerars A; Bast B; de Gast B
Clin Exp Immunol; 1992 Dec; 90(3):368-75. PubMed ID: 1281055
[TBL] [Abstract][Full Text] [Related]
16. Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody.
Hekman A; Honselaar A; Vuist WM; Sein JJ; Rodenhuis S; ten Bokkel Huinink WW; Somers R; Rümke P; Melief CJ
Cancer Immunol Immunother; 1991; 32(6):364-72. PubMed ID: 1706642
[TBL] [Abstract][Full Text] [Related]
17. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.
Schmidt-Wolf IG; Negrin RS; Kiem HP; Blume KG; Weissman IL
J Exp Med; 1991 Jul; 174(1):139-49. PubMed ID: 1711560
[TBL] [Abstract][Full Text] [Related]
18. Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation.
Lauria F; Raspadori D; Ventura MA; Rondelli D; Zinzani PL; Gherlinzoni F; Miggiano MC; Fiacchini M; Rosti G; Rizzi S; Tura S
Bone Marrow Transplant; 1996 Jul; 18(1):79-85. PubMed ID: 8831999
[TBL] [Abstract][Full Text] [Related]
19. Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo.
Schneekloth C; Körfer A; Hadam M; Lopez Hänninen E; Menzel T; Schomburg A; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
Acta Haematol; 1993; 89(1):13-21. PubMed ID: 7683166
[TBL] [Abstract][Full Text] [Related]
20. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
Khan KD; Emmanouilides C; Benson DM; Hurst D; Garcia P; Michelson G; Milan S; Ferketich AK; Piro L; Leonard JP; Porcu P; Eisenbeis CF; Banks AL; Chen L; Byrd JC; Caligiuri MA
Clin Cancer Res; 2006 Dec; 12(23):7046-53. PubMed ID: 17145827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
